MedTrace Logo

Observational Study to Evaluate the Efficacy of Sustained QUTENZA® Use in Painful Diabetic Peripheral Neuropathy

NCT06495424 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 144

Last updated 2026-04-21

No results posted yet for this study

Summary

The purpose of this post-market observational study is to provide real-world evidence to support the repeated use of QUTENZA in patients with PDPN and to evaluate the potential for pain and concomitant medication use reduction.

Conditions

  • Peripheral Diabetic Neuropathy
  • Painful Diabetic Neuropathy

Interventions

DRUG

Capsaicin 8%

Repeat applications every 12 weeks in patients with PDPN of the feet.

Sponsors & Collaborators

  • Averitas Pharma, Inc.

    lead INDUSTRY

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-03-14
Primary Completion
2027-03-01
Completion
2027-03-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06495424 on ClinicalTrials.gov